AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19793860 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (FA; 400 microg)
Number of subjects: 272
Study 19793860 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA)
Number of subjects: 272
Study 16409326 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: immersion in 24% H(2)O(2) for 10 min and silanization for 60 s
Number of subjects: 110
Study 16409326 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: immersion in 10% H(2)O(2) for 20 min and silanization for 60 s
Number of subjects: 110
Study 16409326 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: immersion in 4% hydrofluoric acid gel for 60 s and silanization for 60 s
Number of subjects: 110
Study 16409326 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: silanization of the post surface for 60 s and application of the bonding agent G-Bond
Number of subjects: 110
Study 16409326 — intervention group
Group type: COMPARATOR
Intervention: Group 5: silanization of the post surface for 60 s (control group)
Number of subjects: 110
Study 15243010 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release methylphenidate (MPH), 1.0 mg/kg, once daily
Number of subjects: 12
Study 15243010 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 12
Study 11804430 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoconazole (400 mg daily) followed by clomiphene (100 mg/day)
Number of subjects: 97
Study 11804430 — intervention group
Group type: COMPARATOR
Intervention: clomiphene without ketoconazole pretreatment
Number of subjects: 97
Study 8988791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 17
Study 8988791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8237838 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 674
Study 8237838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 674
Study 3307550 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 50
Study 3307550 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (2 mg/kg)
Number of subjects: 50
Study 31723996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib and Rituximab
Number of subjects: 0
Study 31723996 — intervention group
Group type: COMPARATOR
Intervention: FCR (Fludarabine, Cyclophosphamide, and Rituximab)
Number of subjects: 0
Study 28437262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture Simulator II (Kyoto Kagaku, Kyoto, Japan)
Number of subjects: 55
Study 28437262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar Epidural Injection Trainer (Erler‐Zimmer, Lauf, Germany)
Number of subjects: 55
Study 28437262 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Adult Lumbar Puncture/Epidural Tissue (Simulab Corp., Seattle, Washington, USA)
Number of subjects: 55
Study 28437262 — intervention group
Group type: COMPARATOR
Intervention: Banana
Number of subjects: 55
Study 26077237 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab monotherapy 10 mg/kg IV every 2 weeks
Number of subjects: 361
Study 26077237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg IV every 2 weeks and temsirolimus 25 mg IV every week
Number of subjects: 361
Study 26077237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 5 mg/kg IV every 2 weeks and sorafenib 200 mg orally twice daily
Number of subjects: 361
Study 26077237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg twice daily and temsirolimus 25 mg IV weekly
Number of subjects: 361
Study 23599320 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL of autologous whole blood injected
Number of subjects: 53
Study 23599320 — intervention group
Group type: COMPARATOR
Intervention: Needling only (control group)
Number of subjects: 53
Study 23599320 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 53
Study 20832982 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-assisted coping skills training (CST)
Number of subjects: 233
Study 20832982 — intervention group
Group type: COMPARATOR
Intervention: Education/support involving the caregiver
Number of subjects: 233
Study 18299548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-arm group (n = 180)
Number of subjects: 376
Study 18299548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeved-arm group (n = 196)
Number of subjects: 376
Study 18299548 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 376
Study 16518424 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical histamine dihydrochloride (HDC) gel
Number of subjects: 45
Study 16518424 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 45
Study 14618033 — intervention group
Group type: COMPARATOR
Intervention: Rate control strategy
Number of subjects: 522
Study 14618033 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control strategy
Number of subjects: 522
Study 14618033 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control therapy
Number of subjects: 522
Study 10755495 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2.5 g/d) + Rosiglitazone (4 mg/d)
Number of subjects: 348
Study 10755495 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2.5 g/d) + Rosiglitazone (8 mg/d)
Number of subjects: 348
Study 10755495 — intervention group
Group type: COMPARATOR
Intervention: Metformin (2.5 g/d) + Placebo
Number of subjects: 348
Study 8969976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (Cognex) treatment
Number of subjects: 0
Study 1624019 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation with buserelin acetate, human menopausal gonadotropins (hMG), and human chorionic gonadotropin (hCG)
Number of subjects: 49
Study 1624019 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (6 months)
Number of subjects: 49
Study 6743467 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinidin durules
Number of subjects: 6
Study 6743467 — intervention group
Group type: EXPERIMENTAL
Intervention: Longacor
Number of subjects: 6
Study 31315577 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational sentence in cover letter
Number of subjects: 25000
Study 31315577 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational sentence mentioning alcohol
Number of subjects: 25000
Study 31315577 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational sentence mentioning stress
Number of subjects: 25000
Study 31315577 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational sentence mentioning sex
Number of subjects: 25000
Study 31315577 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational sentence (general)
Number of subjects: 25000
Study 31315577 — intervention group
Group type: COMPARATOR
Intervention: Control group (generic letter)
Number of subjects: 25000
Study 30427505 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BT-A)
Number of subjects: 36
Study 30427505 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 36
Study 25460342 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM system
Number of subjects: 300
Study 25460342 — intervention group
Group type: COMPARATOR
Intervention: Binder condition
Number of subjects: 300
Study 22880943 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS Symptom Management Manual self-care strategies
Number of subjects: 222
Study 22880943 — intervention group
Group type: COMPARATOR
Intervention: Nutrition manual (control)
Number of subjects: 222
Study 21427328 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced tube voltage (80 or 100 kVp depending on BMI)
Number of subjects: 50
Study 21427328 — intervention group
Group type: COMPARATOR
Intervention: Standard tube voltage (100 or 120 kVp depending on BMI)
Number of subjects: 50
Study 21427328 — intervention group
Group type: COMPARATOR
Intervention: Standard tube voltage
Number of subjects: 50
Study 21427328 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced tube voltage
Number of subjects: 50
Study 21427328 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced tube current
Number of subjects: 50
Study 21427328 — intervention group
Group type: COMPARATOR
Intervention: Standard tube current
Number of subjects: 50
Study 18703571 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental care (DC)
Number of subjects: 179
Study 18703571 — intervention group
Group type: COMPARATOR
Intervention: Standard care (C)
Number of subjects: 179
Study 17969466 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction combined with 0.035 g/dL low-dose alcohol
Number of subjects: 21
Study 17969466 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction combined with 0.025 g/dL low-dose alcohol
Number of subjects: 21
Study 17969466 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep without alcohol
Number of subjects: 21
Study 17969466 — intervention group
Group type: COMPARATOR
Intervention: Sleep restriction alone (4 hours)
Number of subjects: 21
Study 13680286 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy with oral PSK (3 g per day) followed by oral 5‐FU (200 mg/body per day)
Number of subjects: 446
Study 13680286 — intervention group
Group type: COMPARATOR
Intervention: Intermittent chemotherapy with oral 5‐FU (200 mg per day) followed by 4‐week rest
Number of subjects: 446
Study 11471517 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (Zyvox‐‐Pharmacia)
Number of subjects: 0
Study 9514527 — intervention group
Group type: EXPERIMENTAL
Intervention: GB virus C co-infection
Number of subjects: 160
Study 9514527 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis C infection alone
Number of subjects: 160
Study 9346380 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise renal rehabilitation program (ERRP) consisting of 3 weekly sessions for 6 months
Number of subjects: 31
Study 9346380 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise renal rehabilitation program (ERRP)
Number of subjects: 31
Study 9346380 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control status
Number of subjects: 31
Study 1783082 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 2.5 mg
Number of subjects: 14
Study 1783082 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 5 mg
Number of subjects: 14
Study 1783082 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 7.5 mg
Number of subjects: 14
Study 1783082 — intervention group
Group type: COMPARATOR
Intervention: Placebo elixir
Number of subjects: 14
Study 7113880 — intervention group
Group type: EXPERIMENTAL
Intervention: 10°C water bath exposure
Number of subjects: 31
Study 7113880 — intervention group
Group type: EXPERIMENTAL
Intervention: 14°C water bath exposure
Number of subjects: 31
Study 7113880 — intervention group
Group type: COMPARATOR
Intervention: 22°C water bath exposure
Number of subjects: 31
Study 7113880 — intervention group
Group type: COMPARATOR
Intervention: 26°C water bath exposure
Number of subjects: 31
Study 7113880 — intervention group
Group type: COMPARATOR
Intervention: 34°C water bath exposure
Number of subjects: 31
Study 7113880 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 31
Study 30925876 — intervention group
Group type: EXPERIMENTAL
Intervention: CBG-CS-2 (1.68 g/day for 8 weeks)
Number of subjects: 79
Study 30925876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 79
Study 30076607 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERGROWTH-21st
Number of subjects: 9409
Study 30076607 — intervention group
Group type: EXPERIMENTAL
Intervention: National Institute of Child Health and Human Development
Number of subjects: 9409
Study 30076607 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO fetal growth standards
Number of subjects: 9409
Study 26771888 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying at least one minor allele of rs2069762 (G) in IL2
Number of subjects: 205
Study 26771888 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying two copies of the minor allele of rs1800871 (T) of IL10
Number of subjects: 205
Study 26771888 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying the minor allele of rs486907 (A) in RNASEL
Number of subjects: 205
Study 26771888 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score from the three SNPs possibly associated with inflammation
Number of subjects: 205
Study 25114296 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira + metformin
Number of subjects: 413
Study 25114296 — intervention group
Group type: COMPARATOR
Intervention: IDeg + metformin
Number of subjects: 413
Study 22934754 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rapamycin (0.003% and 0.015%)
Number of subjects: 23
Study 22934754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no rapamycin)
Number of subjects: 23
Study 20358335 — intervention group
Group type: EXPERIMENTAL
Intervention: Transulnar percutaneous pinning
Number of subjects: 100
Study 20358335 — intervention group
Group type: COMPARATOR
Intervention: Transarticular bridging external fixation
Number of subjects: 100
Study 20358335 — intervention group
Group type: COMPARATOR
Intervention: Ulnar styloid fracture with radius fracture treated by external fixation
Number of subjects: 100
Study 20358335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar styloid fracture with radius fracture treated by pinning
Number of subjects: 100
Study 20358335 — intervention group
Group type: COMPARATOR
Intervention: No ulnar styloid fracture with radius fracture treated by pinning or external fixation
Number of subjects: 100
Study 17234653 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 40
Study 17234653 — intervention group
Group type: COMPARATOR
Intervention: Control group (immediate clamping)
Number of subjects: 40
Study 16186438 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty in high-risk group
Number of subjects: 1527
Study 16186438 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis in high-risk group
Number of subjects: 1527
Study 16186438 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty in low-risk group
Number of subjects: 1527
Study 16186438 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis in low-risk group
Number of subjects: 1527
Study 12153372 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) use
Number of subjects: 508
Study 12153372 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics, military service, military-related health outcomes, and physician-diagnosed health complaints
Number of subjects: 508
Study 12153372 — intervention group
Group type: EXPERIMENTAL
Intervention: Current high daily stress, perceived negative impact of military life on physical or mental health, and physician-diagnosed chronic illnesses
Number of subjects: 508
Study 12153372 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictor variables from regression analysis
Number of subjects: 508
Study 9752983 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy intake (six dairy servings/day)
Number of subjects: 40
Study 9752983 — intervention group
Group type: COMPARATOR
Intervention: Low dairy intake (<0.5 serving of dairy products/day)
Number of subjects: 40
Study 7948057 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental day-treatment group
Number of subjects: 0
Study 7948057 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard inpatient care
Number of subjects: 0
Study 3354317 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-flanged nail
Number of subjects: 21
Study 3354317 — intervention group
Group type: COMPARATOR
Intervention: Three screws
Number of subjects: 21
Study 3354317 — intervention group
Group type: EXPERIMENTAL
Intervention: Hammering of the nail
Number of subjects: 21
Study 29433562 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy for 2 weeks
Number of subjects: 0
Study 29433562 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (NC)
Number of subjects: 0
Study 27455955 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly for 12 weeks followed by etanercept 25 mg twice weekly for 12 weeks (ETN-ETN)
Number of subjects: 60
Study 27455955 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly plus acitretin 10 mg twice daily for 24 weeks (ETN-ACT)
Number of subjects: 60
Study 27455955 — intervention group
Group type: COMPARATOR
Intervention: Acitretin 10 mg twice daily for 24 weeks (ACT)
Number of subjects: 60
Study 24558091 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of lesions using FLAIR imaging
Number of subjects: 143
Study 24558091 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of relative signal intensity (rSI) of 1.20
Number of subjects: 143
Study 24558091 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of rSI measurements into visual evaluation
Number of subjects: 143
Study 22633033 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised care of cognitive behaviour therapy with sound-focused tinnitus retraining therapy
Number of subjects: 492
Study 22633033 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 492
Study 21098771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination training (aerobic and resistance training)
Number of subjects: 262
Study 21098771 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 262
Study 21098771 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 262
Study 21098771 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise groups
Number of subjects: 262
Study 21098771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination training
Number of subjects: 262
Study 21098771 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 262
Study 18455287 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose containing drink
Number of subjects: 0
Study 18455287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15966464 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP301 5 mg
Number of subjects: 0
Study 15966464 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP301 20 mg
Number of subjects: 0
Study 15966464 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP301 40 mg
Number of subjects: 0
Study 15966464 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP301 60 mg
Number of subjects: 0
Study 15966464 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP301 (all doses)
Number of subjects: 0
Study 15966464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12820458 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for infectious foci (chest and sinus roentgenograms, ENT surgeon visit, dentist visit)
Number of subjects: 73
Study 12820458 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 73
Study 10689613 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewed by case managers
Number of subjects: 78
Study 10689613 — intervention group
Group type: COMPARATOR
Intervention: Interviewed by external researchers
Number of subjects: 78
Study 8929751 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use in case of illness during pregnancy before admission to hospital for delivery
Number of subjects: 300
Study 8929751 — intervention group
Group type: COMPARATOR
Intervention: Drug administration under delivery
Number of subjects: 300
Study 8929751 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy of chronic diseases in pregnancy
Number of subjects: 300
Study 8929751 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of nursing women
Number of subjects: 300
Study 1626679 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% prilocaine
Number of subjects: 10
Study 1626679 — intervention group
Group type: COMPARATOR
Intervention: 0.5% chloroprocaine
Number of subjects: 10
Study 6538742 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat (75 g)
Number of subjects: 49
Study 6538742 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (equivalent protein content to meat)
Number of subjects: 49
Study 6538742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cauliflower (65 mg ascorbic acid)
Number of subjects: 49
Study 6538742 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure ascorbic acid (50 mg)
Number of subjects: 49
Study 6538742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (6 mg)
Number of subjects: 49
Study 6538742 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid (1 g)
Number of subjects: 49
Study 31590286 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie ketogenic (VLCK) diet
Number of subjects: 79
Study 31590286 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie (LC) diet
Number of subjects: 79
Study 30059778 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Steroids (ES)
Number of subjects: 30
Study 30059778 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study 25952591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic standing practice in a modified standing frame
Number of subjects: 28
Study 25952591 — intervention group
Group type: COMPARATOR
Intervention: Static standing practice in a conventional standing frame
Number of subjects: 28
Study 24170109 — intervention group
Group type: EXPERIMENTAL
Intervention: NKB (2.56 or 5.12 nmol/kg/h)
Number of subjects: 34
Study 24170109 — intervention group
Group type: COMPARATOR
Intervention: NKB (5.12 nmol/kg/h)
Number of subjects: 34
Study 24170109 — intervention group
Group type: EXPERIMENTAL
Intervention: NKB (0.64‐5.12 nmol/kg/h)
Number of subjects: 34
Study 22556176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 210
Study 20132136 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional progressive resistance exercise (PRE) strength training for 12 weeks, three times a week, on a five‐exercise circuit
Number of subjects: 51
Study 20132136 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual care
Number of subjects: 51
Study 20132136 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional progressive resistance exercise (PRE) strength training
Number of subjects: 51